SUPPLEMENTAL BALANCE SHEET INFORMATION

Inventories

Inventories consisted of the following:



	April 30, 2017	October 31, 2016
	$	$
Raw materials, packaging components and spare parts	228.7	192.1
Work-in-process	92.3	80.9
Finished goods	130.6	122.2
Balance, end of period	451.6	395.2

Accounts payable and accrued liabilities

Accounts payable and accrued liabilities consisted of the following:



	April 30, 2017	October 31, 2016
	$	$
Trade payables	277.1	279.3
Interest payable	9.8	14.0
Accrued salaries and related expenses	78.8	81.8
Customer deposits	4.1	4.3
Repositioning	4.9	5.4
Other accruals	7.5	8.8
Balance, end of period	382.2	393.6

Intangible assets

The following table summarizes gross carrying amounts, accumulated amortization, and accumulated impairments related to the Company's identifiable intangible assets as of April 30, 2017:



Definite-lived intangible assets	Gross carrying value	Accumulated amortization		Net carrying value		Weighted Average Useful Life (in Years)
	$	$		$
Favorable agreements	1.0	(1.0	)	—		—
Trade names	1.6	(0.9	)	0.7		5.6
Developed technology	54.1	(19.4	)	34.7		10.8
Trade secrets and patents	2.5	(0.4	)	2.1		14.5
Customer relationships	248.8	(49.5	)	199.3		14.2
Non-compete agreements	2.6	(2.2	)	0.4		3.0
Subtotal	310.6	(73.4	)	237.2
Foreign exchange				(3.3	)
Balance, end of period				233.9



Indefinite-lived intangible assets	Gross carrying value	Accumulated impairment		Net carrying value
	$	$		$
In-process research and development	2.2	(0.9	)	1.3
Regulatory permits	0.2	—		0.2
Subtotal	2.4	(0.9	)	1.5
Foreign exchange				(0.2	)
Balance, end of period				1.3

In-process research and development (“IPR&D”) is classified as definite-lived or indefinite-lived depending on whether the product has been approved and if commercialization has begun. IPR&D for products that have been approved is classified as a definite-lived intangible asset and is amortized over the life of the asset. IPR&D for products that have not been approved is classified as an indefinite-lived intangible asset and either begins to be amortized upon approval and product commercialization or is written-off if the product is not approved.

In the first quarter of fiscal 2016, the Company sold an IPR&D asset to Banner Life Sciences for cash consideration equal to its net carrying value of $3.6 million. At the time of the sale, the asset had a gross carrying value of $7.9 million and had incurred $4.3 million in impairments.

Goodwill

The following table summarizes the changes in the carrying amount of goodwill for the six months ended April 30, 2017:



	Total
	$
Balance at October 31, 2016 ⁽¹⁾	281.6
Foreign currency translation adjustments	(0.2	)
Balance at April 30, 2017	281.4

(1) The opening cumulative goodwill balance is reflective of historical impairment charges of the full value of goodwill.